---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-164015"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:22:49.021879+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Tempest: amezalpat 6-month OS improvement in HCC (21 vs 15 months); files $205M equity facility

## Summary
- Median OS 21 months for amezalpat arm vs 15 months control, a six-month advantage.
- Hazard ratio of 0.65 for OS, stable from 0.59 at primary analysis 10 months earlier.
- 20/40 amezalpat patients remain in survival follow-up vs 9/30 control.
- Entered new Open Market Sale Agreement to sell up to $205M of common stock.
- Tempest retains all product rights; data supports potential pivotal Phase 3.

## SEC filing metadata
- accession: 0001193125-24-164015
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/0001193125-24-164015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312524164015/d857887d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-164015
- JSON: https://secwatch.observer/filing/0001193125-24-164015.json
- Plain text: https://secwatch.observer/filing/0001193125-24-164015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.